Upgrade to SI Premium - Free Trial

Replimune (REPL)

11.99 +0.27 (2.30%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 October 22, 2026 8:01 AM - Globe NewsWire Replimune Group (REPL) Reiterated at Overweight by Cantor Fitzgerald on Tudriqev Launch October 5, 2026 7:46 AM - StreetInsider Replimune's TUDRIQEV now available in U.S. for advanced melanoma October 1, 2026 4:01 PM - StreetInsider Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma October 1, 2026 4:01 PM - Globe NewsWire Form 8-K Replimune Group, Inc. For: Sep 15 September 16, 2026 4:05 PM - SEC Filing Replimune Group (REPL) PT Raised to $21 at JPMorgan August 26, 2026 8:49 AM - StreetInsider Form 4 Replimune Group, Inc. For: Aug 20 Filed by: Astley-Sparke Philip August 24, 2026 7:49 PM - SEC Filing Form 4 Replimune Group, Inc. For: Aug 17 Filed by: Hill Emily Luisa August 19, 2026 6:42 PM - SEC Filing Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 19, 2026 4:01 PM - Globe NewsWire Form S-3ASR Replimune Group, Inc. August 14, 2026 4:53 PM - SEC Filing Form 10-Q Replimune Group, Inc. For: Jun 30 August 14, 2026 4:13 PM - SEC Filing Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: Ridgeback Capital Investments L.P. August 14, 2026 4:02 PM - SEC Filing Form 8-K Replimune Group, Inc. For: Aug 14 August 14, 2026 8:11 AM - SEC Filing Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update August 14, 2026 8:00 AM - Globe NewsWire Form 4 Replimune Group, Inc. For: Aug 10 Filed by: Patel Sushil August 12, 2026 5:08 PM - SEC Filing Form 4 Replimune Group, Inc. For: Aug 10 Filed by: Hill Emily Luisa August 12, 2026 5:07 PM - SEC Filing Form 4 Replimune Group, Inc. For: Aug 10 Filed by: Xynos Konstantinos August 12, 2026 5:05 PM - SEC Filing Form 4 Replimune Group, Inc. For: Aug 10 Filed by: Schwendenman Andrew August 12, 2026 5:04 PM - SEC Filing Replimune Group (REPL) Reiterated at Overweight by Cantor Fitzgerald August 12, 2026 7:37 AM - StreetInsider Form SCHEDULE 13D/A Replimune Group, Inc. Filed by: BAKER BROS. ADVISORS LP August 11, 2026 5:51 PM - SEC Filing Form 4 Replimune Group, Inc. For: Aug 11 Filed by: BAKER JULIAN August 11, 2026 5:46 PM - SEC Filing Form 8-K/A Replimune Group, Inc. For: Aug 09 August 11, 2026 6:03 AM - SEC Filing Form SCHEDULE 13G Replimune Group, Inc. Filed by: GOLDMAN SACHS GROUP INC August 10, 2026 8:34 PM - SEC Filing Replimune prices $150M stock offering at $12.06 per share August 10, 2026 8:01 AM - StreetInsider Replimune Announces Pricing of $150 Million Underwritten Offering August 10, 2026 8:00 AM - Globe NewsWire Form 8-K Replimune Group, Inc. For: Aug 09 August 10, 2026 7:50 AM - SEC Filing Form 424B5 Replimune Group, Inc. August 10, 2026 7:39 AM - SEC Filing Form SCHEDULE 13G Replimune Group, Inc. Filed by: STATE STREET CORP August 7, 2026 10:51 AM - SEC Filing Replimune Group (REPL) PT Raised to $20 at JPMorgan August 7, 2026 9:09 AM - StreetInsider Replimune Group (REPL) PT Raised to $20 at BMO Capital August 7, 2026 8:10 AM - StreetInsider Wedbush Upgrades Replimune Group (REPL) to Outperform August 7, 2026 6:21 AM - StreetInsider Form 8-K Replimune Group, Inc. For: Aug 06 August 7, 2026 6:05 AM - SEC Filing Replimune (REPL) call put ratio 1 call to 5.8 puts with a focus on August 7 weekly 9 puts and August 14 weekly 2 puts August 7, 2026 4:47 AM - StreetInsider Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: MONTANOVA CAPITAL, LLC August 6, 2026 5:48 PM - SEC Filing FDA grants accelerated approval to Replimune's Tudriqev for melanoma August 6, 2026 4:00 PM - StreetInsider Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen August 6, 2026 4:00 PM - Globe NewsWire FDA approves Replimune melanoma therapy in combo with nivolumab August 6, 2026 3:59 PM - StreetInsider Leerink Upgrades Replimune Group (REPL) to Outperform August 4, 2026 3:43 AM - StreetInsider Piper Sandler Upgrades Replimune Group (REPL) to Overweight July 31, 2026 8:53 AM - StreetInsider Wedbush Upgrades Replimune Group (REPL) to Outperform July 31, 2026 6:47 AM - StreetInsider Form 8-K Replimune Group, Inc. For: Jul 30 July 31, 2026 6:05 AM - SEC Filing Cantor Fitzgerald Upgrades Replimune Group (REPL) to Overweight July 31, 2026 3:54 AM - StreetInsider FDA advisory panel votes 10-3 in favor of Replimune's melanoma drug July 30, 2026 6:15 PM - StreetInsider Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma July 30, 2026 6:15 PM - Globe NewsWire Form 8-K Replimune Group, Inc. For: Jul 30 July 30, 2026 8:06 AM - SEC Filing Form EFFECT Replimune Group, Inc. July 30, 2026 6:05 AM - SEC Filing Replimune (REPL) call put ratio 1 call to 3.7 puts as share price down 9% July 29, 2026 10:44 AM - StreetInsider Form ARS Replimune Group, Inc. For: Mar 31 July 29, 2026 6:02 AM - SEC Filing Form DEFA14A Replimune Group, Inc. July 29, 2026 6:02 AM - SEC Filing Form DEF 14A Replimune Group, Inc. For: Sep 15 July 29, 2026 6:02 AM - SEC Filing Replimune stock tumbles 20% after FDA raises efficacy concerns July 28, 2026 7:40 AM - StreetInsider Replimune (REPL) Weakness Tied to FDA Briefing Documents, Shares -18% July 28, 2026 7:30 AM - StreetInsider Replimune (REPL) files for 25.1M share offering by selling stockholders July 24, 2026 5:01 PM - StreetInsider Form S-3/A Replimune Group, Inc. July 24, 2026 4:58 PM - SEC Filing Full Article List